Clinical trials in Alicante – page 4

316 clinical trials in Alicante, Spain across 4 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in SpainEnsayosClinicos.es

Alicante at a glance

316

clinical trials

Research sites4

Quick filters

316 trials in Alicante

Open in trial search

Acute myeloid leukaemia

Recruiting

A study comparing venetoclax, azacitidine, and quizartinib versus venetoclax and azacitidine in newly diagnosed acute myeloid leukemia patients not suitable for standard chemotherapy

InvestigationalNo placebo

A study comparing venetoclax, azacitidine, and quizartinib versus venetoclax and azacitidine in newly diagnosed acute myeloid leukemia patients not suitable for standard chemotherapy

InvestigationalNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Quizartinib Dihydrochloride
Sponsor:Fundacion PETHEMA

Contact Research Centre

Acute myeloid leukaemia

Recruiting

A Study Comparing Two Treatment Schedules of Venetoclax and Azacitidine in Adults with Newly Diagnosed Acute Myeloid Leukemia Not Suitable for Intensive Treatment

Registered drugNo placebo

A Study Comparing Two Treatment Schedules of Venetoclax and Azacitidine in Adults with Newly Diagnosed Acute Myeloid Leukemia Not Suitable for Intensive Treatment

Registered drugNo placebo

Spain

Participants:65+ years
Substances:Azacitidine
Sponsor:Institut Gustave Roussy

Contact Research Centre

HIV infection

Recruiting

A study testing VH4524184 with emtricitabine and tenofovir alafenamide compared to dolutegravir and lamivudine in adults with HIV-1 who have not received treatment before

Registered drugNo placebo

A study testing VH4524184 with emtricitabine and tenofovir alafenamide compared to dolutegravir and lamivudine in adults with HIV-1 who have not received treatment before

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Dolutegravir Sodium
Sponsor:Viiv Healthcare UK Limited

Contact Research Centre

HER2 positive breast cancer

Recruiting

Study of Trastuzumab Deruxtecan and Pertuzumab for Patients with HER2-Positive Metastatic Breast Cancer Who Have Not Received Prior Treatment

Registered drugNo placebo

Study of Trastuzumab Deruxtecan and Pertuzumab for Patients with HER2-Positive Metastatic Breast Cancer Who Have Not Received Prior Treatment

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Pertuzumab
Sponsor:Solti Group

Contact Research Centre

Hypertrophic cardiomyopathy+1

Recruiting

A study testing ninerafaxstat compared to placebo in patients with symptomatic non-obstructive hypertrophic cardiomyopathy

Investigational

A study testing ninerafaxstat compared to placebo in patients with symptomatic non-obstructive hypertrophic cardiomyopathy

Investigational

Spain

Participants:18–64 years · 65+ years
Sponsor:Imbria Pharmaceuticals Inc.

Contact Research Centre

Small cell lung cancer limited stage

Recruiting

Study of tarlatamab maintenance treatment after chemotherapy and radiation therapy in patients with limited stage small cell lung cancer who cannot receive both treatments together

InvestigationalNo placebo

Study of tarlatamab maintenance treatment after chemotherapy and radiation therapy in patients with limited stage small cell lung cancer who cannot receive both treatments together

InvestigationalNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Tarlatamab
Sponsor:Fundacion GECP

Contact Research Centre

Mantle cell lymphoma

Recruiting

Study of Glofitamab and Pirtobrutinib Treatment in Patients with Mantle Cell Lymphoma Who Have Failed Previous Therapy and in Previously Untreated Patients

Registered drugNo placebo

Study of Glofitamab and Pirtobrutinib Treatment in Patients with Mantle Cell Lymphoma Who Have Failed Previous Therapy and in Previously Untreated Patients

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Glofitamab
Sponsor:Klinikum der Universitaet Muenchen AöR

Contact Research Centre

Non-small cell lung cancer+5

Recruiting

Study of cemiplimab treatment after surgery in patients with stage II-IIIA non-small cell lung cancer who have not received chemotherapy and have PD-L1 expression of 1% or higher

Registered drugNo placebo

Study of cemiplimab treatment after surgery in patients with stage II-IIIA non-small cell lung cancer who have not received chemotherapy and have PD-L1 expression of 1% or higher

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Cemiplimab
Sponsor:ETOP IBCSG Partners Foundation

Contact Research Centre

Non-small cell lung cancer

Recruiting

Study comparing QL2107 and pembrolizumab in patients with resected non-small cell lung cancer receiving adjuvant therapy

Registered drugNo placebo

Study comparing QL2107 and pembrolizumab in patients with resected non-small cell lung cancer receiving adjuvant therapy

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Pembrolizumab
Sponsor:Qilu Pharmaceutical Co. Ltd.

Contact Research Centre

Dermatitis atopic

Recruiting

Study of GHZ339 for treatment of moderate to severe atopic dermatitis

Registered drug

Study of GHZ339 for treatment of moderate to severe atopic dermatitis

Registered drug

Spain

Participants:18–64 years · 65+ years
Substances:GHZ339
Sponsor:Novartis Pharma AG

Contact Research Centre

Rhinitis allergic+1

Recruiting

Study of sublingual immunotherapy with Dermatophagoides pteronyssinus and Dermatophagoides farinae allergen mix for patients with dust mite allergic rhinitis

Investigational

Study of sublingual immunotherapy with Dermatophagoides pteronyssinus and Dermatophagoides farinae allergen mix for patients with dust mite allergic rhinitis

Investigational

Spain

Participants:0–17 years · 18–64 years
Substances:Sodium Chloride
Sponsor:Advanced Outcomes Research S.L.

Contact Research Centre

Non-small cell lung cancer

Recruiting

Safety and feasibility study of fecal microbiota transplant in stage II-III non-small cell lung cancer patients treated with durvalumab, carboplatin, paclitaxel and rifaximin

Registered drugNo placebo

Safety and feasibility study of fecal microbiota transplant in stage II-III non-small cell lung cancer patients treated with durvalumab, carboplatin, paclitaxel and rifaximin

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Fundacion GECP

Contact Research Centre

Other cities in Spain

The busiest research cities in the country

All 218 cities in Spain

Clinical research in Alicante

What the registry says about research in the country

01 Oncology Research

Current studies focus on advanced treatments for non-small cell lung cancer, including both early-stage and metastatic cases. Investigations are ongoing in acute myeloid leukemia and lymphoma treatments.

Lung Cancer Therapies
Blood Cancer Treatments
Immunotherapy Approaches

Research emphasizes innovative combination therapies and targeted treatments for better patient outcomes.

02 Dermatological Studies

Comprehensive research into treatments for plaque psoriasis and atopic dermatitis, with multiple trials evaluating new therapeutic approaches for moderate to severe cases.

Psoriasis Management
Dermatitis Treatments
Prurigo Nodularis Research

Studies focus on developing effective solutions for chronic skin conditions.

03 Cardiovascular Research

Investigations into hypertrophic cardiomyopathy and post-heart attack treatments, including studies on specialized stent therapies and antiplatelet medications.

Heart Disease Management
Cardiomyopathy Treatment
Post-Infarction Care

Focus on improving outcomes for patients with various cardiac conditions.

04 Immunology and Allergies

Clinical trials examining treatments for allergic rhinoconjunctivitis and responses to various allergens, including specialized immunotherapy approaches.

Allergy Treatments
Immunotherapy Development
Respiratory Conditions

Research aims to improve allergy management and treatment effectiveness.

Back to Spain All countries